|Registry of biomedical companies:
 [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 450 active entries
James Lindsay Place
Dundee DD1 5JJ; U.K.
Phone: +44 1382 206 062
Fax: +44 1382 206 067
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
Cyclacel Limited is a biotechnology company conducting research in cancer therapeutics. Cyclacel’s scientific group is headed by Professor David Lane, one of the founders of the field of cell cycle research. The Company’s research programmes are converting insights in cell cycle control into novel treatments for common cancers. Cyclacel’s world-leading biology is complemented by state-of-the-art rational drug design chemistry. The product portfolio includes small molecule Cyclin-Dependent Kinase (CDK) inhibitor drugs that regulate the cell cycle (CYC200), novel Penetratin™-drug complexes (CYC300), Pimetic™ drugs mimicking natural cancer suppressing proteins (CYC100), and intelligent targeting and delivery systems for cancer therapeutics using its Penetratin and SGC™ technologies.
Last update of this entry: before October 1999.